142 related articles for article (PubMed ID: 20206498)
1. Oxidative stress-induced antioxidant enzyme expression is an early phenomenon in ovarian carcinogenesis.
Pylväs M; Puistola U; Kauppila S; Soini Y; Karihtala P
Eur J Cancer; 2010 Jun; 46(9):1661-7. PubMed ID: 20206498
[TBL] [Abstract][Full Text] [Related]
2. Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours.
Fauvet R; Dufournet C; Poncelet C; Uzan C; Hugol D; Daraï E
J Surg Oncol; 2005 Dec; 92(4):337-43. PubMed ID: 16299808
[TBL] [Abstract][Full Text] [Related]
3. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.
Wang C; Horiuchi A; Imai T; Ohira S; Itoh K; Nikaido T; Katsuyama Y; Konishi I
J Pathol; 2004 Feb; 202(2):215-23. PubMed ID: 14743504
[TBL] [Abstract][Full Text] [Related]
4. Metallothionein expression and nuclear size in benign, borderline, and malignant serous ovarian tumours.
Tan Y; Sinniah R; Bay BH; Singh G
J Pathol; 1999 Sep; 189(1):60-5. PubMed ID: 10451489
[TBL] [Abstract][Full Text] [Related]
5. [Expression of the cdx2 gene in benign intestinal-type mucinous ovarian tumors].
Gaggero G; Sola S; Mora M; Fulcheri E
Pathologica; 2003 Aug; 95(4):185-91. PubMed ID: 14577202
[TBL] [Abstract][Full Text] [Related]
6. Oxidative stress markers and mitochondrial antioxidant enzyme expression are increased in aggressive Hodgkin lymphomas.
Bur H; Haapasaari KM; Turpeenniemi-Hujanen T; Kuittinen O; Auvinen P; Marin K; Koivunen P; Sormunen R; Soini Y; Karihtala P
Histopathology; 2014 Sep; 65(3):319-27. PubMed ID: 24698430
[TBL] [Abstract][Full Text] [Related]
7. Proteomic identification of overexpressed PRDX 1 and its clinical implications in ovarian carcinoma.
Chung KH; Lee DH; Kim Y; Kim TH; Huh JH; Chung SG; Lee S; Lee C; Ko JJ; An HJ
J Proteome Res; 2010 Jan; 9(1):451-7. PubMed ID: 19902980
[TBL] [Abstract][Full Text] [Related]
8. DNA adduct 8-hydroxydeoxyguanosine, a novel putative marker of prognostic significance in ovarian carcinoma.
Karihtala P; Soini Y; Vaskivuo L; Bloigu R; Puistola U
Int J Gynecol Cancer; 2009 Aug; 19(6):1047-51. PubMed ID: 19820366
[TBL] [Abstract][Full Text] [Related]
9. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype.
Kelly PJ; Archbold P; Price JH; Cardwell C; McCluggage WG
J Clin Pathol; 2010 Feb; 63(2):169-73. PubMed ID: 20154039
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of 8-hydroxydeoxyguanosine and peroxiredoxin II in the pathogenesis of endometriosis-associated ovarian cancer.
Sova H; Kangas J; Puistola U; Santala M; Liakka A; Karihtala P
Anticancer Res; 2012 Aug; 32(8):3037-44. PubMed ID: 22843871
[TBL] [Abstract][Full Text] [Related]
11. Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer.
Bostwick DG; Alexander EE; Singh R; Shan A; Qian J; Santella RM; Oberley LW; Yan T; Zhong W; Jiang X; Oberley TD
Cancer; 2000 Jul; 89(1):123-34. PubMed ID: 10897009
[TBL] [Abstract][Full Text] [Related]
12. Morphometry and digital AgNOR analysis in cytological imprints of benign, borderline and malignant serous ovarian tumours.
Stemberger-Papić S; Stanković T; Vrdoljak-Mozetic D; Versa-Ostojić D; Krasević M; Stifter S; Audy-Jurković S
Cytopathology; 2006 Dec; 17(6):382-9. PubMed ID: 17168922
[TBL] [Abstract][Full Text] [Related]
13. Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
Shibata K; Kajiyama H; Mizokami Y; Ino K; Nomura S; Mizutani S; Terauchi M; Kikkawa F
Gynecol Oncol; 2005 Jul; 98(1):11-8. PubMed ID: 15907336
[TBL] [Abstract][Full Text] [Related]
14. Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the iron-induced persistent oxidative stress.
Yamaguchi K; Mandai M; Toyokuni S; Hamanishi J; Higuchi T; Takakura K; Fujii S
Clin Cancer Res; 2008 Jan; 14(1):32-40. PubMed ID: 18172249
[TBL] [Abstract][Full Text] [Related]
15. Clinical factors and biomarkers in ovarian tumors development.
Vrabie CD; Petrescu A; Waller M; Dina I
Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia.
Kalir T; Wang BY; Goldfischer M; Haber RS; Reder I; Demopoulos R; Cohen CJ; Burstein DE
Cancer; 2002 Feb; 94(4):1078-82. PubMed ID: 11920478
[TBL] [Abstract][Full Text] [Related]
17. Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours.
Dong Y; Walsh MD; Cummings MC; Wright RG; Khoo SK; Parsons PG; McGuckin MA
J Pathol; 1997 Nov; 183(3):311-7. PubMed ID: 9422987
[TBL] [Abstract][Full Text] [Related]
18. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
19. Mucin gene transcripts in benign and borderline mucinous tumours of the ovary: an in situ hybridization study.
Boman F; Buisine MP; Wacrenier A; Querleu D; Aubert JP; Porchet N
J Pathol; 2001 Mar; 193(3):339-44. PubMed ID: 11241413
[TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase-2 expression in borderline ovarian tumors.
Ferrandina G; Zannoni GF; Ranelletti FO; Legge F; Gessi M; Salutari V; Gallotta V; Lauriola L; Scambia G
Gynecol Oncol; 2004 Oct; 95(1):46-51. PubMed ID: 15385109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
